Method and system for colloid exchange therapy

Details Method and system for colloid exchange therapy Method and system for colloid exchange therapy

2009-04-17

2010-11-23

Drodge, Joseph W (Department: 1797)

Liquid purification or separation

Processes

Liquid/liquid solvent or colloidal extraction or diffusing...

C210S651000, C424S130100, C424S529000, C604S005010, C604S006010, C604S006090, C604S019000, C530S362000, C514S021800, C514S776000

Reexamination Certificate

active

07837878

ABSTRACT:
The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.

REFERENCES:
patent: 4191182 (1980-03-01), Popovich et al.
patent: 4229291 (1980-10-01), Walch et al.
patent: 4350156 (1982-09-01), Malchesky et al.
patent: 4350594 (1982-09-01), Kawai et al.
patent: 4402940 (1983-09-01), Nose et al.
patent: RE31688 (1984-09-01), Popovich et al.
patent: 4581141 (1986-04-01), Ash
patent: 4648974 (1987-03-01), Rosskopf et al.
patent: 4685900 (1987-08-01), Honard et al.
patent: 4900720 (1990-02-01), Kotitschke
patent: 4966709 (1990-10-01), Nose et al.
patent: 5571418 (1996-11-01), Lee et al.
patent: 5744042 (1998-04-01), Stange et al.
patent: 5783085 (1998-07-01), Fischel
patent: 5919444 (1999-07-01), Norman, Jr.
patent: 6008199 (1999-12-01), Grinnell et al.
patent: 6231536 (2001-05-01), Lentz
patent: 6287516 (2001-09-01), Matson et al.
patent: 6342157 (2002-01-01), Hood
patent: 6736972 (2004-05-01), Matson
patent: 6787040 (2004-09-01), Radunsky et al.
patent: 7291122 (2007-11-01), Matson
patent: 7520992 (2009-04-01), Radunsky et al.
patent: 7524420 (2009-04-01), Radunsky et al.
patent: 2001/0051106 (2001-12-01), Matson
patent: 2004/0060866 (2004-04-01), Radunsky et al.
patent: 2004/0173530 (2004-09-01), Radunsky et al.
patent: 2009/0204050 (2009-08-01), Radunsky et al.
patent: 2495459 (2004-02-01), None
patent: 787500 (1997-08-01), None
patent: 0739234 (2003-02-01), None
patent: WO 2004/014315 (2004-02-01), None
patent: WO 2004/056460 (2004-07-01), None
patent: WO 2004/112869 (2004-12-01), None
Official Action in European Patent Application No. 02750294.7 dated Sep. 24, 2008 (3 pages).
Bellomo et al., “Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis”; The International Journal Of Artificial Organs, 2005, vol. 28, No. 5, pp. 450-458.
Bellomo et al., “Hemofiltration and Hemoperfusion on Sepsis and Septic Shock,” Acute Dialysis Quality Initiative, 3rd International Consensus Conference, Workgroup 1 (2003) (Date of Conference obtained from ADQI Newsletter found at www.adqi.net/#background).
Bellomo et al.; “An Introduction to Continuous Renal Replacement Therapy”, Atlas of Hemofiltration, p. 1-9, 2002.
Chung et al., “Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study”, Critical Care 2009, 13:R62 (doi: 10.1186/cc7801) (Available online at http://ccforum.com/content/13/3/R62).
Colton, “Analysis of Membrane Processes for Blood Purification,” In-Depth Review 5:202-251 (1987).
Fong et al., “Endotoxemia Elicits Increased Circulating βIFN/IL-6 In Man,” Journal of Immunology vol. 142, 2321-2324, No. 7 (Apr. 1989).
Frigon et al., “Hemofilter Solute Sieving Is Not Governed by Dynamically Polarized Protein,” Trans Am. Soc. Artif. Intern, Organs vol. XXX (1984).
Harris et al., “Manifestations of Sepsis” arch. Intern. Med. vol. 147 (Nov. 1987).
Hinshaw et al. “Extracorporeal Perfusion Without, Exogenous Anticoagulations: Its Protective Role in Endotoxin Shock” Circulatory Shock 9:281-295 (1982).
Hinshaw et al., “Staphylococcus Aureus-Induced Shock: A Pathyphysiologic Study” Circulatory Shock 26:257-265 (1988).
Honore et al., “Extracorporeal removal for sepsis: Acting at the tissue level—The beginning of a new era for this treatment modality in septic shock”, Crit Care Med 2004, Vo. 32, No. 3 (pp. 896-897).
Honore et al., “High Volume and High Permeability Haemofiltration for sepsis: the evidence and the key issues”, Care of the Critically III, Jun. 2003, vol. 19, No. 3.
Honore et al., “Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the homodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock”, Crit. Care Med 2000 vol. 28, No. 11, pp. 3581-3587.
Honore et al.; “Hemofiltration, absorption, sieving and the challenge of sepsis therapy design”, Critical Care, Oct. 2006, vol. 6, No. 5.
Honore et al.; “Short-Term High-Volume Hemofiltration in Sepsis: Perhaps the Right Way Is to Start With . . . ”, Letters to the Editor, Crit Care Med 2002, vol. 20, No. 7 (pp. 1673-1677).
Lee et al., “Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy forStaphylococcus aures-induced septicemia in immature swine”, Crit Care Med 1998, vol. 26, No. 4 (pp. 730-737).
Lee et al., “Continuous Arteriovenouse Hemofiltration (CAVH) Therapy for Sepsis-Induced Acute Lung Injury in Immature Swine”, FASEB J., 1990 4(4) SUPPL: A953.
Leypoldt, et al., “Dextran Sieving Coefficients of Hemofiltration Membranes” Trans. Am. Soc. Artif. Inter. Organs vol. XXX (1983).
Matson et al.; “Evolving concepts of therapy for sepsis and septic shock and the sue of hypermeable membranes”, Curr Opin Crit Care 2000, 6:432-436.
Matson et al; “Blood filtration: new opportunities and the implications of systems biology”, Critical Care and resuscitation 2004; 6:207-207.
Michie et al., “Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration,” New Eng. Journal of Medicine 318:1481-1486 (Jun. 1988).
Parsonett et al., “Induction of Interleukin-1 by Strains ofStaphylococcus arueusfrom Patients with Nonmenstrual Toxic Shock Syndrome”, Journal of Infectious Diseases 124:1 (Jul. 1986).
Sheagren, “Staphylococcus areusThe Persistent Pathogen” New Eng. Journal of Medicine 310:21 (May 1984).
Shumak and Rock, “Therapeutic Plasma Exchange” New Eng. Journal of Medicine 213:12 (Mar. 1984).
Sporn, et al. “Continuous Pump Driven Hemofiltration (CPDHF) in Septic Renal Failure,” First Vienna Shock Forum, Part B: Monitoring and Treatment of Shock, pp. 225-233 (1987).
Todd et al., “Recovery From Endotoxin Shock After Extracorporeal Perfusion Without Anticoagulation,” Circulatory Shock 6:261-269 (1979).
Weinstein et al., “The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Influencing Prognosis” Reviews of Infectious Disease 5:1 (Jan.-Feb. 1983).
F. Coraim; R. Fasol; F. Stellwag; E. Wolner;Continuous Arteriovenous Hemofiltration(CAVH)After Cardiac Surgery; Clinic for Anesthesia and General Intensive Care Medicine and 2nd Surgical Clinic, University of Vienna Austria. Continuous Arteriovenous Hemofiltration (CAVH); Int. conf. on CAVH, Aachen 1984, pp. 116-124 (Karger, Basel 1985). (9 pages).
W.F. Koller; H.M. Benzer; G.F. Pauser;CAVH in Acute Respiratory Failure; Research Center for Intensive Care medicine, 2ndSurgical Clinic, University of Vienna, Vienna, Austria; Continuous Arteriovenous Hemofiltration (CAVH); Int. Conf. on CAVH, Aachen 1984; pp. 96-102 (Karger, Basel 1985). (7 pages).
G. Zobel; E. Ring; M. Kutting; H.M. Grubbauer;Five years experience with continuous extracorporeal renal support in paediatric intensive care; (Received 1990; Accepted Feb. 3, 1991; Department of Paediatrics, University of Graz, Austria); Intensive Care Medicine; 1993 17:315-319. (5 pages).
Patrice A. Lee PhD; James R. Matson, MD; Robert W. Pryor, MD, FCCM; Lerner B. Hinshaw, PhD, FCCM;Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine; Critical Care Medicine 1993; vol. 21, No. 6. (11 pages).
Non-final Office Action date mailed Sep. 29, 2008 for U.S. Appl. No. 11/934,978.
Response filed Mar. 30, 2009 for U.S. Appl. No. 11/934,978.

Affiliated with

Also associated with

Rating

Method and system for colloid exchange therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and system for colloid exchange therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and system for colloid exchange therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4175587